My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  collaboration  alliances  partnering  alliance  alliance managers  partner  partners  alliance manager  partnerships  ecosystem  The Rhythm of Business  partnership  governance  Jan Twombly  Strategic Alliance Magazine  Eli Lilly and Company  biopharma  Vantage Partners  IoT  ASAP BioPharma Conference  Healthcare  NetApp  strategy  2015 ASAP Global Alliance Summit  Cisco  communication  IBM  innovation  Christine Carberry 

Academia and Industry—Creating a Seamless Fit (Part Two)

Posted By Genevieve Fraser, Wednesday, June 7, 2017

In the session “Making the Most of Industry-Academia Collaborations,” Mark Coflin, CSAP, head of alliance management at Shire Pharmaceuticals was joined by his colleague, Joe Sypek, PhD, director and external science lead at Shire, as they explored cultural differences between partners in academia and industry working together to find a cure for a disease (see Part I of this blog post) http://www.strategic-alliances.org/blogpost/1143942/277595/Academia-and-Industry-Partnerships-Creating-a-Seamless-Fit--Part-I. Joining them at the 2017 ASAP Global Alliance Summit, “Profit, Innovation, and Value for the Part­nering Enterprise,” were Sanford Burnham Prebys Medical Discovery Institute’s (SBP’s) Paula Norris, PhD, laboratory director and project manager, and Sarah Hudson, PhD, R&D project and operations associate director. The 2017 Summit was held Feb. 28-March 2 in San Diego, Calif.

 

Norris works with principal investigators (PIs) to develop strategic plans for lab operations and policies. On any given project, she might work with four or five partners at a time. Some are smaller start-up companies; others are larger pharmaceutical companies. “In the past, we were grant-centric, but now less so as we work with industries,” she explained. “We explore a partner’s expectations, then go back to our group and discuss what we need to do to make it work. But there’s a language gap with industry. The language in industry is not necessarily the same as ours. So at times, there’s miscommunication. But we’ve gotten better at asking questions about what they mean, especially when we’re not sure [of] what they want or their end goal.”

 

“We’ve spent time working on culture and skill seton education across the institute. For example, what is a hit or lead?” she asked rhetorically. “We need to educate in terms of the basic terms of an alliance partner’s language.”

 

“It’s also important to hone in on expectations. If partners have different expectations, it can cause problems,” Norris stated. “Instead of going off on a tangent, we need to understand the scope and what the goals are and stay focused. Otherwise, we will fail to line up with the milestones. The criteria are only met when the milestone is achieved. “

 

“It can be a challenge if a partner says it’s a ‘no go,’ and we think there is an avenue. We need to remember that the money comes from a partner. If there’s scope creep, we need to draw them back to achieve the milestone. To do that you must have the right people involved and have communicated broadly. You need to define the statement of workmake sure the language is conciseso both parties are clear about what they need to do for the project.”

 

Hudson acknowledged that she and Norris are proud of the innovation and knowledge base of PIs, but to retain the culture, academia must adapt to make industry-academia projects run more smoothly. This only happens if someone is designated as the point person: “It’s quite important for long-term capabilities. A manager makes sure deadlines are met for milestones.”

As the leader of the project manager group at SBP, Hudson’s role is to partner with scientific project leaders in collaborations and initiatives. “These pharmaceutical and biotech companies, as well as alliances with other academic institutions, all have the same flavor but run differently,” Hudson conceded. “So, we do what we must to adapt with projects run by a joint steering committee.”

It’s important not to assume everything is going well, Coflin added.  As in every kind of relationship, the person talking needs to be truthful so that members of the team come to you with issues.  Being a good partner involves communicationsmonthly meetings. “Scientists tend to be reserved so they won’t get scooped. You need to create trust. Labs operate in a silo working by themselves, but to have an effective partnership, you need to work in a collaborative environment,” he said.

 

Scientists need to develop basic alliance management skills, Hudson stressed. “Because we don’t have large infrastructure, it’s important that we impart these skills to scientists so we can be proactive, instead of merely responsive.”

 

Since their groups have been working on alliance skills, both Hudson and Norris have personally seen a difference in greater productivity and efficiency through collaboration as their projects progress.

 

Sypek agrees that things break down when there is a lack of communication. If you are to reach the next level, you need to feel comfortable about talking with partners, he said. “The more you communicate, the better you get. But each project must be treated as individual, as unique, especially if the PI and/or goals are different.”

 

“What you are doing is transformative to an institution, Coflin stated. “Just as we do at Shire, you must prepare your institution to partner. Despite the fact they might be uncomfortable, it’s important to give them tools to be ready to partner. That sort of preparation is how you build capability.”

 

The entire panel then agreed on one axiom: A common goal helps make it work!

Part I of this blog post focuses on Shire Pharmaceutical’s perspective on academic-industry partnerships. http://www.strategic-alliances.org/blogpost/1143942/277595/Academia-and-Industry-Partnerships-Creating-a-Seamless-Fit--Part-I

Tags:  alliance partners  alliance skills  biotech  collaboration  communication  Joe Sypek  Mark Coflin  partner  partner language  partners  Paula Norris  principal investigators  Sanford Burnham Prebys Medical Discovery Institute  Sarah Hudson  Shire Pharmaceuticals  transformation 

Share |
PermalinkComments (0)
 

Academia and Industry Partnerships—Creating a Seamless Fit (Part I)

Posted By Genevieve Fraser, Friday, June 2, 2017

Though their organizations are quite different, the shared goal partners in an academia-industry life sciences alliance is to find a cure to address the disease, emphasized Mark Coflin, CSAP, an oncologist and head of alliance management at Shire Pharmaceutical, during a candid, rapid-fire discussion on the cultural differences between academia and industry. Coflin kicked off a session featuring several panelists  discussing “Making the Most of Industry-Academia Collaborations” during thePartnering for Performance in Life Sciences” track at the 2017 ASAP Global Alliance Summit, “Profit, Innovation, and Value for the Part­nering Enterprise,” Feb. 28-March 2 in San Diego, Calif.

 

Joining Coflin on the panel was Paula Norris, PhD, laboratory director and project manager at Sanford Burnham Prebys Medical Discovery Institute (SBP); Sarah Hudson, PhD, a biochemist, organic chemist, and associate director of R&D projects and operations at SBP; Joe Sypek, PhD, director and external science lead, comparative immunology at Shire Pharmaceuticals. The pharmaceutical company is dedicated to creating specialized medicines for patients with rare diseases.

 

Coflin opened the discussion with a major consideration for this kind of partnership: “From the science side, when you’re handed a project, if you haven’t been involved from the beginning, it’s difficult,” he offered. “Having someone on the alliance side helps a lot.”  Coflin said he has managed some one-off projects, but for the most part, his target institutions are involved with pediatric research where he is responsible for putting agreements together.

 

Sypek’s role at Shire is to identify and foster new academic alliance partnerships. This complex of new partnerships, in turn, feeds the early-discovery stage pipeline in the rare disease space within discovery biology and transitional research.  Shire’s milestone-based agreements are tied to contingent payments for each gene target if specified research, regulatory, clinical development, commercialization, and sales milestone events occur.

 

“We’ve tried other models,” Sypek said. “Each institution has nuances. Each has upfront money and needs money to start up. So, we start with initial payments and set the budget, year to year.”

 

“We do milestones because we need to get meaningful data.  We want data that is robust and statistically significant. If it doesn’t work out, the principle investigator (PI) can take the project and partner with someone else,” Sypek continued. “Treatments are an internal project that require regular lab meetings. Both parties must be committed to getting to goals, but all projects have regular meetings where we try to pour all necessary resources together for success.”

 

When setting up a team, if it doesn’t have a molecule, Shire might outsource and pay for its development, even if it’s outside of the budget.  In 2012, Shire entered a broad, three-year research collaboration in rare diseases with Boston Children’s Hospital, and since then has expanded to other pediatric hospitals. 

 

“Shire’s plan is to cast a broad net to get the best of the best to target the disease. That’s what the intentions are, but what are the challenges?” Sypek asked.

 

“Central to the challenges are the cultural differences between academia and industry. But the goal for both parties is to find a cure to address the disease,” Sypek concluded. “You can work for years in a lab, but it’s the research collaboration that allows a breakthrough [to be] possible. Today, academia seeks out industry partners. The boundary walls are not as high as they use to be. They are more in tune to working with industry. NIH budgets can be tight, and there are always questions about what might happen to funding. That’s where industry might be able to step in and fund research and materials.”

Part II of this blog post focuses on Sanford Burnham Prebys Medical Discovery Institute’s perspective on academic-industry partnerships. 

Tags:  academia  alliance  Boston Children’s Hospital  collaboration  Joe Sypek  partner  Paula Norris  pediatric research  research  Sanford Burnham Prebys Medical Discovery Institute  Sarah Hudson  Shire Pharmaceuticals 

Share |
PermalinkComments (0)
 
For more information email us at info@strategic-alliances.org or call +1-781-562-1630